A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2018
At a glance
- Drugs SRP-5051 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Sarepta Therapeutics
- 14 Dec 2017 Status changed from planning to recruiting.
- 14 Nov 2017 New trial record
- 07 Nov 2017 According to a Sarepta Therapeutics media release, the U.S. FDA has cleared its Investigational New Drug IND application.